JASIS2024 Highlights in the Field of Life Sciences

Introduction

I am Hisashi Iwase, Life Science Innovation Advisor for the Japan Analytical Instruments Manufacturers’ Association (JAIMA) and President & CEO of BioDiscovery Inc.

Looking back at the history of analysis, it began with questions like, “What is this made of?” and “What compounds does this contain?” Through chemistry and physics, analysis has developed as “the science of understanding the components and mechanisms within.” In drug development, chromatography and mass spectrometry technologies have contributed immensely to drug discovery and pharmaceutical technologies. Over the past 20 years, advancements in analytical instrumentation and chemical analysis technologies have played a major role in the rapidly advancing field of biosciences. Since the late 1980s, innovations in technology have begun to uncover the structures and functions of genes and proteins, and since the completion of the human genome sequencing in 2003, we have seen an era of rapid evolution and practical application, supported by advances in ICT.

On January 30, 2015, President Obama announced the “Precision Medicine Initiative” in his State of the Union Address, with NIH allocating significant funding for large-scale epidemiological research. As of 2024, this initiative has steadily progressed, intersecting with single-cell analysis, spatial transcriptomics, and various imaging technologies and AI applications, bringing clinical omics research closer to realization.

JASIS2024 Highlights in Life Sciences

At JASIS2024, held as a starting point in the post-COVID-19 era, we have gathered nearly the same number of exhibitors and participating companies as in 2019. A new, globally oriented industry-academia collaboration program from Japan has been planned. The event aims to accelerate DX primarily through automation, and in the field of life sciences, pharmaceutical development will feature groundbreaking technologies for generating polymorphs in small molecule drugs. For biopharmaceuticals, the Topic Seminars and the JAIMA/Japan Society for Biotechnology Joint Pitch Networking, co-hosted for the third time this year, are organized in collaboration with the Japan Society for Biotechnology. I am confident that these initiatives will revive the “Japan as No.1” era in analytical instruments, with globally recognized Japanese technology.

JAIMA/Japan Society for Biotechnology Joint Pitch Networking

Networking for “Finding Seeds of Innovation” between Biotechnology and Analytical Industries

Japan has a globally recognized potential in fermentation science. JAIMA has been promoting alliance projects with the Japan Society for Biotechnology, which began in the field of fermentation. At JASIS2024, we will hold a joint Pitch Networking event called “Finding Seeds of Innovation.”

The program consists of presentations (first half) and networking (second half), providing a space for four pitch speakers to discuss collaboration opportunities in depth.

Location: TKP Tokyo Bay Makuhari Hall 1F Cotswolds (next to APA Hotel Makuhari)
Capacity: Advance registration required; limited to the first 50 registrants
Participation Fee: ¥5,000 (includes food and drinks, tax included)
Register here: Registration opens July 15 (Register via this link)
Organizers: JAIMA Technical Committee, Life Science Subcommittee
JASIS Committee Organizer Subcommittee

JASIS Square Lecture

“Latest Trends and Future Challenges in Metabolome Analysis Technology”
Date: Friday, September 6, 2024, 10:30–11:30
Location: JASIS Square, A Stage, Makuhari Messe Exhibition Hall

Lecture Content
This lecture will introduce the latest trends in instrumental analysis technology in metabolomics (metabolome analysis), alongside a discussion on key technologies needed for next-generation metabolome analysis. The importance of developing new metabolome analysis technologies will be highlighted, with discussion on challenges and efforts in technological development.
Speaker: Kenji Baba, Professor, Kyushu University Research Institute for Microbial Diseases

JASIS2024 Square Venue Map
JASIS2024 Square Venue Map

Topic Seminar

Theme: Cutting-Edge Research in Crystalline Polymorphism in Pharmaceutical Development

~ Innovative Technologies for Creating Unprecedented Crystalline Polymorphs in Small Molecules ~
International Conference Hall, September 5, 10:30–12:00

  • Lecture 1. “Crystalline Polymorphism and Global Trends in Patent Strategy”
    Yasuko Tanaka, Director and Patent Attorney, S Cube International Patent Office
  • Lecture 2. “New Technology for Crystal Formation” (Tentative)
    Professor Nobuaki Tounai, Graduate School of Engineering, Osaka University
  • Lecture 3. “Challenges in Crystalline Polymorphism in Pharmaceuticals”
    ~ Late-Appearing Polymorphs, Crystalline Polymorph Identification ~ (Tentative)
    Mitsuhisa Yamano, Chief Researcher, Spera Pharma Co., Ltd., Pharmaceutical Research Division

Theme: DX in Pharmaceutical Manufacturing

International Conference Hall, September 6, 13:00–14:30

  • Lecture 1. “AI Drug Discovery and Data Integration”
    Professor Kenji Mizuguchi, Protein Research Institute, Osaka University
  • Lecture 2. “Digitalization Transformation in the Biopharmaceutical Industry”
    Jinhong (Andrew) Kim, Director, Atkins Réalis, Industrial South Korea
  • Lecture 3. “Accelerating Manufacturing DX with Process Informatics”
    Professor Manabu Kano, Graduate School of Informatics, Kyoto University
PROFILE

Mr. Hisashi Iwase

Life Science Innovation Advisor, Japan Analytical Instruments Manufacturers’ Association (JAIMA), President & CEO of BioDiscovery Inc.
Born in 1951, Tokyo. Graduated from Nihon University, Department of Industrial Chemistry, College of Science and Technology. His career in managing and marketing analytical and bioscience instruments includes roles at Merck Japan, Waters Japan, Millipore Japan, Perceptive Japan, Applied Biosystems, Varian Technologies, and Agilent Technologies. Established BioDiscovery Inc. in 2001. Since 2013, he has also served as Life Science Innovation Advisor for JAIMA.

Back to Home Page